dmd
Reading File
Finding Sources
Searching PubMed
"Duchenne muscular dystrophy" treatment
Reading File
Reading File
Here is a comprehensive overview of Duchenne Muscular Dystrophy (DMD):
Duchenne Muscular Dystrophy (DMD)
Overview
DMD is the most common inherited muscle disease, with an incidence of approximately 1 in 5,000 male births (some sources cite up to 1 in 500, reflecting differences in birth screening vs. diagnosed cohorts). It follows an X-linked recessive pattern - the dystrophin gene is located at Xp21.2 and is one of the largest genes in the human genome. About one-third of cases arise from de novo mutations with no family history.
Pathophysiology
A frameshift mutation in the DMD gene results in complete absence of the dystrophin protein. Dystrophin normally forms a mechanical link between the intracellular sarcomere and the sarcolemma (the muscle cell membrane). Without it:
- The sarcolemma becomes structurally unstable
- Calcium leaks into the cell
- This triggers muscle fiber necrosis
- Repeated cycles of degeneration and regeneration cause progressive replacement of muscle tissue by adipose and connective tissue
Becker MD (BMD) is the allelic but milder variant - caused by in-frame mutations that allow production of a partially functional (truncated) dystrophin.
Clinical Features
| Feature | Details |
|---|---|
| Onset | 2-5 years of age |
| Early signs | Delayed motor milestones, frequent falls, difficulty climbing stairs |
| Gowers' sign | Child uses hands to "walk up" their own legs to rise from the floor |
| Calf pseudohypertrophy | Replacement of muscle with fat and fibrous tissue |
| Muscle weakness | Proximal > distal; lower limb > upper limb initially |
| Loss of ambulation | Typically by age 10-12 years |
| Scoliosis | Develops after loss of ambulation; worsens respiratory function |
| Cardiomyopathy | Dilated cardiomyopathy (DCM); affects virtually all patients by late teens |
| Respiratory failure | Progressive; noninvasive ventilation often required by late teens/20s |
| Cognitive/behavioral | Lower average IQ, learning disabilities, ADHD, autism - nonprogressive |
Death is primarily from cardiorespiratory failure.
Diagnosis
- Serum CK: Markedly elevated - 20 to 100x normal (often >10x normal even in early childhood). Can be detected from newborn screening dried blood spots.
- DNA analysis (genetic testing): Positive in ~90-95% of patients; identifies deletions, duplications, or point mutations in the DMD gene
- Muscle biopsy (if genetic testing negative): Shows variation in fiber size, necrosis, inflammation, fibrosis, and regeneration. Immunohistochemistry (IHC) shows complete or near-complete absence of dystrophin (carboxy-terminal antigens). Revertant fibers may occasionally stain positive.
- Mean age of diagnosis: ~41 months
Female carriers: Most are asymptomatic. Up to 20% of manifesting carriers may show some muscle weakness or cardiac involvement (DCM). Severe disease in females can result from skewed X-inactivation or X-autosome translocation.
Treatment
Management requires a multidisciplinary team (neurology, cardiology, pulmonology, orthopedics, physiotherapy, psychology, dietetics, speech therapy).
Corticosteroids
- Prednisone 0.75 mg/kg/day - prolongs ambulation; may also slow scoliosis progression and help respiratory function
- Deflazacort 0.9 mg/kg/day - similar efficacy to prednisone with less weight gain; FDA-approved
- Vamorolone - a newer dissociative steroid with a favorable side-effect profile vs. corticosteroids (recent systematic reviews and meta-analyses in 2024-2025 confirm efficacy and better safety [PMID: 39331339, PMID: 39715964])
Exon-Skipping Therapies (FDA conditionally approved)
These are phosphorodiamidate morpholino oligomers (PMOs) that restore the reading frame:
| Drug | Exon skipped | Dose |
|---|---|---|
| Eteplirsen | Exon 51 | 30 mg/kg IV weekly |
| Golodirsen | Exon 53 | 30 mg/kg IV weekly |
| Viltolarsen | Exon 53 | 80 mg/kg IV weekly |
| Casimersen | Exon 45 | 30 mg/kg IV weekly |
Each drug applies to patients with specific exon deletion mutations - expert neurologic consultation required to select the appropriate agent.
Cardiac Management
- ACE inhibitors (e.g., lisinopril) - slow progression of myocardial fibrosis; recommended early even before symptoms
- Beta-blockers - for cardiomyopathy management
- Diuretics as needed
- Cardiac predictors of disease are well-characterized (systematic review: [PMID: 39342355])
Respiratory Care
- Regular pulmonary function monitoring
- Noninvasive ventilation (BiPAP) when FVC declines
- Cough assist devices to prevent atelectasis
Orthopedic Management
- Physical therapy to prevent contractures
- Ankle-foot orthoses (AFOs)
- Monitoring for scoliosis - spinal fusion if indicated
- Appropriate wheelchair provision
Emerging Therapies
- Gene therapy approaches (micro-dystrophin AAV vectors) are in clinical trials
- Newborn screening for DMD is under active development in the US (pilot programs showed success in Ohio)
Genetics and Inheritance
- X-linked recessive - females are typically carriers, males are affected
- ~33% de novo mutations (no family history)
- The DMD gene is among the largest in the human genome, spanning >2.4 Mb at Xp21.2
- Frameshift mutations → DMD (no functional protein)
- In-frame mutations → Becker MD (partial function retained)
Sources: Goldman-Cecil Medicine International Edition; Tietz Textbook of Laboratory Medicine, 7th Ed.; Recent PubMed systematic reviews (2024-2025)
Frameshift mutations → DMD (no functional protein)
The reading frame rule (Monaco hypothesis) explains this well:
Why Frameshift → DMD and In-frame → BMD
The Dystrophin Gene and Reading Frame
The DMD gene encodes dystrophin by reading codons (triplets of nucleotides) in a continuous sequence. The ribosome reads the mRNA one codon at a time.
Frameshift Mutations (→ DMD)
A frameshift occurs when a deletion or duplication involves a number of nucleotides not divisible by 3. This shifts the reading frame downstream of the mutation, so:
- Every codon after the mutation is now misread
- A premature stop codon is almost inevitably encountered shortly after
- The result is either no protein (nonsense-mediated mRNA decay degrades the aberrant transcript) or a truncated, non-functional protein
- Dystrophin is completely absent → severe phenotype = DMD
Example: A deletion of exons 48-50 removes a number of nucleotides not divisible by 3 → frameshift → stop codon → no dystrophin
In-frame Mutations (→ BMD)
If the deletion/duplication removes a number of nucleotides exactly divisible by 3, the reading frame is preserved downstream. So:
- Codons after the mutation are still read correctly
- A shorter but partially functional dystrophin protein is produced (with an internal deletion)
- Partial dystrophin = milder phenotype = Becker MD
Example: A deletion of exons 48-49 removes a number of nucleotides divisible by 3 → reading frame intact → truncated but functional dystrophin
The "Reading Frame Rule"
This principle - formulated by Monaco et al. in 1988 - predicts phenotype from genotype:
Frameshift → out-of-frame → no dystrophin → DMD In-frame deletion → partial dystrophin → BMD
This rule holds in ~90% of cases. Exceptions exist (e.g., some in-frame mutations still cause DMD if they affect a critical functional domain of dystrophin, such as the actin-binding domain or cysteine-rich domain).
Why This Matters Clinically
This is the molecular basis for exon-skipping therapy. By using antisense oligonucleotides (e.g., eteplirsen) to force the spliceosome to skip a specific exon, a frameshift mutation in DMD can be converted into an in-frame deletion, effectively converting a DMD genotype into a BMD-like genotype - producing a shorter but partially functional dystrophin.
This is why eteplirsen only works for patients with deletions amenable to exon 51 skipping - it only "fixes" the reading frame for a specific subset of mutations.
This is a shared conversation. Sign in to Orris to start your own chat.